Media coverage about Dimension Therapeutics (NASDAQ:DMTX) has been trending positive recently, Alpha One Sentiment reports. The research group, a division of Accern, identifies negative and positive news coverage by reviewing more than 20 million news and blog sources in real time. Alpha One ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Dimension Therapeutics earned a news sentiment score of 0.39 on Alpha One’s scale. Alpha One also assigned press coverage about the biotechnology company an impact score of 0 out of 100, meaning that recent news coverage is extremely unlikely to have an effect on the company’s share price in the near term.

A number of research firms have commented on DMTX. Zacks Investment Research downgraded Dimension Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, April 4th. Canaccord Genuity set a $20.00 target price on Dimension Therapeutics and gave the stock a “buy” rating in a report on Saturday, March 11th. Cantor Fitzgerald set a $3.00 target price on Dimension Therapeutics and gave the stock a “hold” rating in a report on Saturday, March 11th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and set a $7.00 target price on shares of Dimension Therapeutics in a report on Thursday, February 2nd. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Dimension Therapeutics has a consensus rating of “Hold” and an average price target of $9.10.

Shares of Dimension Therapeutics (NASDAQ:DMTX) traded down 3.23% during mid-day trading on Tuesday, hitting $1.50. The company had a trading volume of 21,922 shares. The firm’s market cap is $37.56 million. The firm’s 50 day moving average is $1.76 and its 200-day moving average is $3.85. Dimension Therapeutics has a 12-month low of $1.35 and a 12-month high of $10.47.

Dimension Therapeutics (NASDAQ:DMTX) last announced its quarterly earnings results on Thursday, March 9th. The biotechnology company reported ($0.53) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.03. Dimension Therapeutics had a negative return on equity of 50.07% and a negative net margin of 464.39%. The company earned $4.10 million during the quarter, compared to analysts’ expectations of $3.04 million. On average, equities analysts expect that Dimension Therapeutics will post ($1.82) EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Dimension Therapeutics (DMTX) Getting Positive Press Coverage, Analysis Finds” was published by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright law. The original version of this news story can be viewed at

Dimension Therapeutics Company Profile

Dimension Therapeutics, Inc is a gene therapy company. The Company is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa).

5 Day Chart for NASDAQ:DMTX

Receive News & Ratings for Dimension Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dimension Therapeutics Inc and related companies with's FREE daily email newsletter.